The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• DPY30 is a subunit of the SET1/MLL complex, regulating histone H3K4 methylation.
• DPY30 dysfunction is implicated in cancer immune evasion.
• The specific role of DPY30 in programmed cell death ligand 1 (PD-L1) expression remains underexplored.

Purpose of the Study:

• To investigate the role of DPY30 in regulating PD-L1 expression in melanoma.
• To elucidate the molecular mechanisms linking DPY30 to PD-L1 expression and cancer immunity.

Main Methods:

• Analysis of DPY30 and PD-L1 expression in melanoma using online databases (UALCAN, Oncomine, cBioPortal, SangerBox, TISIDB, TIMER, GEPIA) and immunohistochemistry (IHC).
• Chromatin Immunoprecipitation (ChIP), RT-PCR, and flow cytometry to determine the regulatory mechanism.
• DPY30 silencing using siRNA and co-culture assays with T-cells.

Main Results:

• DPY30 mRNA levels are higher in melanoma than normal tissues and positively correlate with tumor mutational burden (TMB), neoantigens, and PD-L1 expression.
• DPY30 expression is associated with immune suppressor cells and T-cell exhaustion markers.
• DPY30 overexpression correlates with PD-L1 expression in melanoma tissues (62% vs 58% positive rates).
• DPY30 silencing significantly reduces PD-L1 expression.
• ChIP assays show H3K4me3 enrichment at the PD-L1 promoter upon DPY30 inhibition.
• DPY30 inhibition reduces PD-L1 levels and decreases apoptosis of PD1+ T-cells.

Conclusions:

• DPY30 plays a significant role in regulating cancer immune evasion in melanoma by modulating PD-L1 expression.
• The DPY30-H3K4me3 axis is a potential therapeutic target to enhance checkpoint immunotherapy efficacy.